FDA Breast Implant Decisions Cleared By Senate Panel

Law360, New York (July 31, 2006, 12:00 AM EDT) -- One year after the U.S. Food and Drug Administration gave two companies conditional approval to market silicone breast implants, a U.S. Senate panel has concluded after conducting an investigation into alleged improprieties that the agency’s decisions regarding the controversial product should not be reversed.

Chairman Michael B. Enzi of the Senate Health, Education, Labor and Pensions Committee released the findings of an investigation late last week in a report titled “Pre-Market Approval Applications for Silicone Breast Implants.”

The probe was prompted after more than two dozen...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.